Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study
ConclusionsTepotinib shows dose proportionality up to at least the therapeutic dose, and time-independent clearance with a profile appropriate for once-daily dosing. None of the covariates identified had a clinically meaningful effect on tepotinib exposure or required dose adjustments.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Drugs & Pharmacology | Epithelial Cancer | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Study